Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 5 - The Untold Story

Stock Index Futures Slip on Trump Tariffs, Powell’s Testimony on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release…

Barchart

Gilead Sciences Stock: Is Wall Street Bullish or Bearish?

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

Barchart

Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

StockNews.com

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Barchart

Looking At Gilead Sciences's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

Benzinga

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Fewest New HIV Cases Since Late 1980s: UNAIDS Report

Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.

International Business Times

'Remarkable Global Progress': HIV Cases And Deaths Declining

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.

International Business Times

Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

StockNews.com

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

The Independent UK

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

Barchart

Is Gilead Sciences Stock Underperforming the Dow?

Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has underperformed the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'

A study shows that a twice-yearly shot was 100% effective in preventing new HIV infections in women in Africa

International Business Times

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

Barchart

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Barchart

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Barchart

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

International Business Times

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

Barchart

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.